Shots:

• The ongoing P-II ALTITUDE trial evaluates the efficacy- safety & tolerability of RGX-314 (29.5x1011 GC/eye & 5x1011 GC/eye in cohorts 1 & 2) using SCS microinjection vs observational control in a ratio (3:1) in 20 patients (cohort 1 & 2) with DR without CI-DME
• As of Sept 29- 2021- RGX-314 was well tolerated in 15 patients in cohort 1 out of which 5 patients (33%) demonstrated a ≥2 step improvement from baseline on ETDRS-DRSS @3mos. & 1 patient had a 4-step improvement
• Additionally- 7 & 8 patients who had NPDR & PDR at baseline- 3 patients (43%) & 2 patients (25%) demonstrated a ≥2 step improvement @3mos. while cohort 2 & 3 continue to enroll patients at 5x1011 GC/eye dose

  | Ref: PR Newswire | Image: Biospace